Development and validation of new tests
Critical for product success and market entry
- Materiality
- high
Immunovia
Immunovia AB is a diagnostic company focused on increasing survival rates for patients with pancreatic cancer through early detection. The company specializes in developing and commercializing blood-based tests that detect proteins and antibodies indicative of pancreatic cancer in high-risk individuals. Immunovia collaborates with healthcare providers, leading experts, and patient advocacy groups to make its tests widely available. The company's shares are listed on Nasdaq Stockholm, and it is headquartered in Lund, Sweden.
13
5.12
5.02
| % | |
|---|---|
| Diagnostic Tests | 70% Blood-based tests for detecting pancreatic cancer |
| Clinical Data Services | 20% Services providing clinical data and testing results |
| Strategic Partnerships | 10% Collaborations for commercialization and distribution |
Immunovia's primary customers are healthcare providers and medical centers that focus on high-risk pancreatic cancer...
- Healthcare Providersprimary
Purchase PancreaSure for early detection in high-risk patients
- Medical Centersprimary
Integrate tests into surveillance protocols
- Diagnostics Companiessecondary
Collaborate for commercialization and distribution
- Patient Advocacy Groupsemerging
Support awareness and adoption of testing solutions
Immunovia is headquartered in Lund, Sweden, and its primary market is the United States, which is the largest market...
- •Headquartered in Lund, Sweden
- •Primary market is the United States for pancreatic cancer detection
- •1.8 million high-risk individuals in the USA for surveillance testing
- •Exploring global distribution through strategic partners
Immunovia's strategic priorities include the commercialization of its PancreaSure test, securing strategic...
01
Commercialize PancreaSure testshort-term
To increase market penetration and revenue
02
Secure strategic partnershipsmedium-term
To expand commercial reach and reduce costs
03
Achieve reimbursementmedium-term
To enhance test adoption and financial sustainability
Immunovia faces several operational and financial risks, including the development and validation of new tests,...
Market acceptance and reimbursement
Essential for revenue generation and growth
- Materiality
- high
Currency risks
Exposure to USD and EUR affects financial results
- Materiality
- medium
Revenue recognition
high
Lease accounting
medium
CellaVision
CEVI.ST · Health Care
CellaVision is a global medical technology company specializing in the development and sale of advanced solutions for the routine analysis of blood and other body fluids.
Cantargia
CANTA.ST · Health Care
Cantargia is a Swedish biotechnology company focused on developing targeted antibody-based drugs for cancer, immunological, and other life-threatening diseases.
IQVIA HOLDINGS INC.
IQV · Services-Commercial Physical & Biological Research
Immunovant, Inc.
IMVT · Biological Products, (No Diagnostic Substances)
TuHURA Biosciences, Inc./NV
HURA · Pharmaceutical Preparations
TuHURA Biosciences, Inc./NV is a Nevada-based clinical-stage immuno-oncology company focused on developing therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies.
IMMUNIC, INC.
IMUX · Pharmaceutical Preparations
: 11/08/2026